Dopamine transporter-immunoreactive neurons decrease with age in the human substantia nigra

Journal of Comparative Neurology

Volumn 409, Issue 1, 1999, Pages 25-37

  Ma, S Y ^a   Ciliax, B J ^b   Stebbins, G ^a   Jaffar, S ^a   Joyce, J N ^b   Cochran, E J ^a   Kordower, J H ^a   Mash, D C ^c   Levey, A I ^b   Mufson, E J ^a,d  

^a Rush Alzheimers Disease Center   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c SUN HEALTH RESEARCH INSTITUTE   (United States)

^d RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Aging; Brainstem; Dopamine; Immunocytochemistry; Optical disector; Stereology

Indexed keywords

DOPAMINE TRANSPORTER;

ADOLESCENT; ADULT; AGE; AGED; AGING; ARTICLE; CHILD; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; PRIORITY JOURNAL; SUBSTANTIA NIGRA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; CARRIER PROTEINS; CHILD; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; NEURONS; SUBSTANTIA NIGRA;

EID: 0033591617     PISSN: 00219967     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-9861(19990621)409:1<25::AID-CNE3>3.0.CO;2-E     Document Type: Article

References (58)

1. Bannon MJ, Whitty CJ. 1997. Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Neurology 48:969-977.
2. Bannon MJ, Poosch MS, Xia Y, Goebel DJ, Cassin B, Kapatos G. 1992. Dopamine transporter mRNA content in human substantia nigra decreases precipitously with age. Proc Natl Acad Sci USA 89:7095-7099.
3. Bannon MJ, Granneman JG, Kapatos G. 1995. The dopamine transporter: potential involvement in neuropsychiatric disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press, Ltd.
4. Bloom FE, Young WG, Nimchinsky EA, Hof PR, Morrison JH. 1997. Neuronal vulnerability and informatics in human disease. In: Koslow SH, Huert MF, editors. Progress in neuroinformatics research, vol 1. Neuroinformatics - an overview of the human brain project. Mahwah: Lawrence Erlbaum. p 83-123.
5. Cavalieri B. 1966. Geometria degli indivisibli. Torino: Unione Tipografico, Editrice, p 1-543.
6. Cheramy A, Leviel V, Glowinski J. 1981. Dendritic release of dopamine in the substantia nigra. Nature 289:537-542.
7. Ciliax BJ, Heilman C, Demchyshyn LL, Pristupa ZB, Ince E, Hersch SM, Niznik HB, Levey AI. 1995. The dopamine transporter: immunochemical characterization and localization in brain. J Neurosci 15:1714-1717.
8. Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, Mufson EJ, Mash DM, Levey AI. 1999. Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol 409:38-56.
9. Cochran EJ, Fox JH, Mufson EJ. 1994. Severe panencephalic Pick's disease with Alzheimer's-like neuropil threads and synaptophysin immunoreactivity. Acta Neuropathol Berlin 88:479-484.
10. Coggeshall RE. 1992. A consideration of neural counting methods. Trends Neurosci 15:9-13.
11. Coggeshall RE, Lekan HA. 1996. Methods for determining numbers of cells and synapses: a case for more uniform standards of review. J Comp Neurol 364:6-15.
12. Critchley M. 1956. Neurological changes in the aged. J Chron Dis3:459-477.
13. deKeyser J, Ebinger G, Vauquelin G. 1990. Age-related changes in the human nigrostriatal dopaminergic system. Ann Neurol 27:157-161.
14. Emborg M, Ma S, Mufson EJ, Levey AI, Taylor M, Brown D, Holden J, Kordower JH. 1998. Age-related decline in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 401:253-265.
15. Fearnley JM, Lees AJ. 1991. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 114:2283-2301.
16. Gainetdinov RR, Fumagalli F, Wang Y-M, Jones SR, Caron MG. 1997. Dopamine transporter is required for in vivo MPTP neurotoxicity: evidence from mice lacking the transporter. J Neurochem 69:1322-1325.
17. Gainetdinov RR, Fumagalli F, Wang Y-M, Jones SR, Levey AI, Miller GW, Caron MG. 1998. Increased MPTP neurotoxicity in vesicular monoamine transporter 2 heterozygote knockout mice. J Neurochem 70:1973-1978.
18. German DC, Manaye K, Smith WK, Woodward DJ, Saper CB. 1989. Midbrain dopaminergic cell loss in Parkinson's disease: computer visualization. Ann Neurol 26:507-514.
19. German DC, Manaye KF, Sonsalla PK, Brooks BA. 1992. Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann NY Acad Sci 648: 42-62.
20. German DC, Nelson EL, Liang CL, Speciale SG, Sinton CM, Sonsalla PK. 1996. The neurotoxin MPTP causes degeneration of specific nucleus A8, A9 and A10 dopaminergic neurons in the mouse. Neurodegeneration. 5:299-312.
21. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. 1996. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379:606-612.
22. Guillery RW, Herrup K. 1997. Quantification without pontification: choosing a method for counting objects in sectioned tissues. J Comp Neurol 386:2-7.
23. Gundersen HJG. 1986. Stereology of arbitrary particles: a review of unbiased number and size estimators and the presentation of some new ones, in memory of William R. Thompson. J Microsci 143:3-45.
24. Gundersen HJG, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcussen M, Mfller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sftensen FB, Vesterby A, West MJ. 1988. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 96:857-881.
25. Hancock JC. 1982. A serotonin-like immunoreactive fiber system in the dorsal columns of the spinal cord. Neurosci Lett 31:247-252.
26. Hersch SM, Yi H, Heilman CJ, Edwards RH, Levey AI. 1997. Subcellular localization and molecular topology of the dopamine transporter in the striatum and substantia nigra. J Comp Neurol 388:211-227.
27. Hof PR, Mufson EJ, Morrison JH. 1995. Human orbitofrontal cortex cytoarchitecture and quantitative immunochemical parcellation. J Comp Neurol 359:48-68.
28. Javitch JA, Uhl GR, Synder SH. 1984. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6 tetrahydropyridine: characterization and localization of receptor binding sites in rat and human brain. Proc Natl Acad Sci USA 81:4591-4595.
29. Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH. 1985. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proc Natl Acad Sci USA 82:2173-2177.
30. Joyce JN, Smutzer G, Whittey C, Myers A, Bannon MJ. 1997. Differential modification of dopamine transporter and tyrosine hydroxylase mRNAs in midbrain of subjects with Parkinson's, Alzheimer with Parkinsonism and Alzheimer's disease. Movement Dis 12:855-897.
31. Ma SY, Collan Y, Roytta M, Rinne JO, Rinne UK. 1995a. Neuronal loss in the substantia nigra: a comparison of single section counts and disector counts in patients with Parkinson's disease. Neuropathol Appl Neurobiol 21:10-17.
32. Ma SY, Roytta M, Rinne JO, Collan Y, Rinne UK. 1995b. Single section and disector counts in evaluating neuronal loss from the substantia nigra in patients with Parkinson's disease. Neuropathol Appl Neurobiol 21:341-343.
33. Ma SY, Roytta M, Rinne JO, Collan Y, Rinne UK. 1997. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J Neurol Sci 151:83-87.
34. McGeer PL, McGeer EG, Suzuki JS. 1977. Aging and extrapyramindal function. Arch Neurol 34:33-35.
35. Miller GW, Staley JK, Heilman CJ, Perez JT, Mash DC, Rye DB, Levey AI. 1997. Immunochemical analysis of dopamine transporter protein in Parkinson's disease. Ann Neurol 41:530-539.
36. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L. 1991. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD): part II. standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41:479-486.
37. Mortimer JA. 1988. Human motor behavior and aging. Ann NY Acad Sci 515:54-66.
38. Mufson EJ, Mash DC, Hersh LB. 1988. Neurofibrillary tangles in cholinergic pedunculopontine neurons in Alzheimer's disease. Ann Neurol 24:623-629.
39. Mufson EJ, Presley LN, Kordower JH. 1991. Nerve growth factor receptor immunoreactivity within the nucleus basalis (Ch4) in Parkinson's disease: reduced cell numbers and colocalization with cholinergic neurons. Brain Res 531:19-30.
40. Mufson EJ, Jaffar S, Ciliax BJ, Joyce JN, Mash CD, Levey AI. 1997. Dopamine transporter (DAT) immunoreactivity within the human substantia nigra decreases with age. Soc Neurosci Abstr 23:1456.
41. Mufson EJ, Jaffar S, Levey AI. 1998. m2 muscarinic acetylcholine receptor immunoreactive neurons are not reduced within the nucleus basalis in Alzheimer's disease: relationship with cholinergic and galaninergic perikarya. J Comp Neurol 392:313-329.
42. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM. 1996. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 16:436-447.
43. Nissbrandt H, Sundstrom E, Jonsson G, Hjorth S, Carlsson A. 1989. Synthesis and release of dopamine in rat brain: comparison between substantia nigra pars compacts, pars reticulata, and striatum. J Neurochem 52:1170-1182.
44. Pakkenberg B, Moller A, Gundersen HJG, Dam AM, Pakkenberg H. 1991. The absolute number of nerve cells in substantia nigra in normal subjects and in patients with Parkinson's disease estimates with an unbiased stereological method. J Neurol Neurosurg Psychiatr 54: 30-33.
45. Rinne JO, Sako E, Paljavi L, Molsa PK, Rinne UK. 1986. Brain dopamine D-2 receptors in senile dementia. J Neurol Transm 65:51-62.
46. 11C] β-CFT is reduced in Alzheimer's disease assessed by positron emission tomography. Neurology 50:152-156.
47. Sanghera MH, Manaye K, McMahon F, Sonsalla PK, German DC. 1997. Dopamine transporter mRNA levels are high midbrain neurons vulnerable to MDTP. Neuro Report 8:3327-3331.
48. Saper CB. 1996. Any way you cut it: a new journal policy for the use of unbiased counting methods. J Comp Neurol 364:5.
49. Saper CB. 1997. Counting on our reviewers to set the standards. J Comp Neurol 386:1.
50. Stuart DA, Oorschot DE. 1995. Embedding, sectioning, immunocytochemical and stereological methods that optimise research on the lesioned adult rat spinal cord. J Neurosci Methods 61:5-14.
51. Takahashi N, Miner LL, Sora I, Uyike H, Revay RS, Kostic V, Jackson-Lewis V, Przedburski S, Uhl GR. 1997. VMAT2 knockout mice: heterozygotes display reduced amphetamine-conditioned reward, enhanced amphetamine locomotion, and enhanced MPTP toxicity. Proc Acad Sci USA 94:9938-9943.
52. Uhl GR. 1998. Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson's disease. Ann Neurol 43:555-560.
53. Uhl GR, Walther D, Mash D, Faucheux B, Javoy-Agid F. 1994. Dopamine transporter messenger RNA in Parkinson's disease and control substantia nigra neurons. Ann Neurol 35:494-498.
54. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Wallace E, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Charney DS, Hoffer PB. 1995. Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CIT SPECT. J Nuclear Med 36:1175-81.
55. Volkow ND, Ding Y-S, Fowler JS, Wang G-J, Logan J, Gatley SJ, Hitzmann R, Smith G, Fields SD, Gur R. 1996. Dopamine transporters decrease with age. J Nuclear Med 37:554-559.
56. West MJ. 1993. New stereological methods for counting neurons. Neurobiol Aging 14:275-285.
57. West MJ, Ostergaard K, Andreassen OA, Finsen B. 1996. Estimation of the number of somatostatin neurons in the striatum: an in situ hybridization study using the optical disector method. J Comp Neurol 370:11-22.
58. Zelnik N, Angel I, Paul SM, Kleinman JE. 1986. Decreased density of human striatal dopamine uptake sites with age. Eur J Pharmacol 126:175-176.